Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients

Benzer Materyaller

• Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS
  Yazar:: Karlsson, Christofer A. Q., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
  Yazar:: Jordan, Stanley C., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation
  Yazar:: Järnum, Sofia, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity
  Yazar:: Winstedt, Lena, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice
  Yazar:: Lin, Jiaxin, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)